Cancel anytime
Adagene Inc (ADAG)ADAG
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/07/2024: ADAG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 4.13% | Upturn Advisory Performance 3 | Avg. Invested days: 26 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/07/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 4.13% | Avg. Invested days: 26 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/07/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 136.35M USD |
Price to earnings Ratio - | 1Y Target Price 10.54 |
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Volume (30-day avg) 37777 | Beta 0.58 |
52 Weeks Range 1.33 - 4.38 | Updated Date 11/8/2024 |
Company Size Small-Cap Stock | Market Capitalization 136.35M USD | Price to earnings Ratio - | 1Y Target Price 10.54 |
Dividends yield (FY) - | Basic EPS (TTM) -0.73 | Volume (30-day avg) 37777 | Beta 0.58 |
52 Weeks Range 1.33 - 4.38 | Updated Date 11/8/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4534.83% |
Management Effectiveness
Return on Assets (TTM) -19.59% | Return on Equity (TTM) -45.7% |
Revenue by Products
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 61470757 | Price to Sales(TTM) 167.15 |
Enterprise Value to Revenue 75.36 | Enterprise Value to EBITDA 1.12 |
Shares Outstanding 44270800 | Shares Floating 23159154 |
Percent Insiders 10.66 | Percent Institutions 25.55 |
Trailing PE - | Forward PE - | Enterprise Value 61470757 | Price to Sales(TTM) 167.15 |
Enterprise Value to Revenue 75.36 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 44270800 | Shares Floating 23159154 |
Percent Insiders 10.66 | Percent Institutions 25.55 |
Analyst Ratings
Rating 4.5 | Target Price 13.77 | Buy 2 |
Strong Buy 2 | Hold - | Sell - |
Strong Sell - |
Rating 4.5 | Target Price 13.77 | Buy 2 | Strong Buy 2 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Adagene Inc. (ADAG): A Comprehensive Overview
Company Profile:
History: Founded in 2015, Adagene Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel antibody-based therapies for cancer and other immune-related diseases.
Core Business: The company leverages its proprietary ADAPT technology platform to engineer and develop next-generation antibody therapeutics with enhanced efficacy, safety, and affordability. Its pipeline includes multiple candidates targeting various cancer types and autoimmune disorders.
Leadership: Adagene's leadership team comprises seasoned industry veterans with expertise in drug discovery, development, and commercialization. Peter Luo serves as the President and CEO, while the board of directors includes prominent figures from the healthcare and investment communities.
Top Products and Market Share:
- Currently, Adagene hasn't launched any commercial products, as they are still in the clinical development stage.
- Their lead product candidate, MGD013, is a BCMA-targeting CAR-T cell therapy undergoing a Phase 2 trial for the treatment of relapsed/refractory multiple myeloma.
- Other promising candidates in their pipeline include MGD007 (EGFR-targeting ADC), MGD019 (Claudin18.2-targeting ADC), and MGD020 (SSTR2-targeting ADC).
- With no marketed products yet, Adagene doesn't hold any market share in the global or US markets.
Total Addressable Market:
- The global oncology market is estimated to reach $228.9 billion by 2026, with the US market representing a significant portion.
- The market for CAR-T cell therapies, a specific focus area for Adagene, is expected to grow at a CAGR of 35.5% during the same period, reaching $7.7 billion by 2026.
- This indicates a large and rapidly growing market potential for Adagene's pipeline of targeted therapies.
Financial Performance:
- As a clinical-stage company, Adagene currently generates no revenue and is yet to achieve profitability.
- The company's financials are primarily driven by research & development expenses and administrative costs.
- Analyzing recent financial statements requires looking at aspects like cash burn, funding rounds, and research & development progress.
Dividends and Shareholder Returns:
- As a pre-revenue company, Adagene doesn't currently offer any dividends to shareholders.
- Shareholder return analysis would involve evaluating stock price performance over various periods, considering the company's stage of development and future potential.
Growth Trajectory:
- Adagene's growth trajectory is primarily based on the progress of its clinical pipeline and potential regulatory approvals for its drug candidates.
- Positive clinical trial results and successful product launches could lead to significant stock price appreciation and revenue generation.
- Partnerships with larger pharmaceutical companies for co-development or licensing agreements could also accelerate growth.
Market Dynamics:
- The biopharmaceutical industry is highly competitive, with numerous companies vying for market share in various therapeutic areas.
- Technological advancements in gene therapy, immunotherapy, and precision medicine are driving innovation and creating new opportunities.
- Adagene needs to demonstrate the efficacy and safety of its therapies while navigating a complex regulatory landscape and intense competition.
Competitors:
- Key competitors in the CAR-T cell therapy space include Gilead Sciences (GILD), Novartis (NVS), Bristol-Myers Squibb (BMY), and Kite Pharma (KITE).
- For other candidates in Adagene's pipeline, competitors include companies like Amgen (AMGN), Regeneron (REGN), and Roche (RHHBY).
- Comparing market share and competitive advantages requires a deeper dive into specific products and target markets.
Potential Challenges and Opportunities:
- Key challenges include successfully navigating clinical trials, obtaining regulatory approvals, and achieving market access for their products.
- Maintaining a strong cash position and securing additional funding to support research and development is crucial.
- Managing competition and differentiating their products based on efficacy, safety, and cost-effectiveness is essential.
- Opportunities lie in the potential for breakthrough therapies addressing unmet medical needs and partnering with larger pharmaceutical companies for broader reach and commercialization expertise.
Recent Acquisitions:
- As of November 2023, Adagene hasn't reported any acquisitions in the last three years.
AI-Based Fundamental Rating:
- Due to the lack of financial history and commercialized products, generating a precise AI-based fundamental rating for Adagene is currently not feasible.
- However, considering factors like the potential of its pipeline, the competitive landscape, and the expertise of its leadership team, a preliminary AI-based rating could potentially fall between 6-8, but this is highly speculative.
Sources and Disclaimers:
- Sources used for this analysis include Adagene Inc.'s official website, SEC filings, industry reports, and news articles.
- This information should not be considered as investment advice, and any financial decisions should be made after thorough due diligence and consulting with a financial professional.
Conclusion:
Adagene Inc. is a promising clinical-stage biopharmaceutical company with a focus on developing innovative antibody-based therapies for unmet medical needs. While its financial performance is currently limited and it faces stiff competition, the potential of its pipeline and the expertise of its leadership team offer intriguing opportunities for growth. However, investors must thoroughly understand the risks associated with investing in a company in its early stages of development.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adagene Inc
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 2021-02-09 | Co- Founder, Chairman, CEO and President of R&D | Dr. Peter P. Luo Ph.D. |
Sector | Healthcare | Website | https://www.adagene.com |
Industry | Biotechnology | Full time employees | 174 |
Headquaters | - | ||
Co- Founder, Chairman, CEO and President of R&D | Dr. Peter P. Luo Ph.D. | ||
Website | https://www.adagene.com | ||
Website | https://www.adagene.com | ||
Full time employees | 174 |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.